Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance

Vaccine

Volumn 29, Issue 26, 2011, Pages 4378-4387

  Kurz, Xavier ^a   Domergue, François ^a   Slattery, Jim ^a   Segec, Andrej ^a   Szmigiel, Agnieszka ^a   Hidalgo Simon, Ana ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

Adverse reactions; EudraVigilance; H1N1 vaccines; Signal detection

Indexed keywords

INFLUENZA VACCINE; WART VIRUS VACCINE;

ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; CONVULSION; DATA EXTRACTION; DEMYELINATION; DNA VIRUS INFECTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECONOMICS; ENCEPHALITIS; EUROPE; FACIAL NERVE PARALYSIS; GUILLAIN BARRE SYNDROME; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HUMAN; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MONITORING; NEURITIS; NONHUMAN; ORTHOMYXOVIRUS INFECTION; PANDEMIC; PAPILLOMA VIRUS; PRESCRIPTIVE AUTHORITY; PRIORITY JOURNAL; PROFESSIONAL DELEGATION; UNCERTAINTY; VASCULITIS;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; EUROPEAN UNION; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; PUBLIC HEALTH; RISK ASSESSMENT; YOUNG ADULT;

EID: 79957846498     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.005     Document Type: Article

References (43)

1. European Medicines Agency. Pandemic Influenza A(H1N1)v vaccines authorised via the core dossier procedure. Explanatory note on scientific considerations regarding the licensing of pandemic A(H1N1)v vaccines. EMEA/608259/2009 rev, [accessed 18.03.11]. http://www.ema.europa.eu/pdfs/human/pandemicinfluenza/60825909en.pdf.
2. European Medicines Agency. Committee for Human Medicinal Products (CHMP) Assessment report for Pandemrix. EMEA/CHMP/619109/2009, [accessed 18.03.11]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000832/WC500095422.pdf.
3. European Medicines Agency. Committee for Human Medicinal Products (CHMP) Assessment report for Focetria. EMEA/CHMP/503605/2009, [accessed 18.03.11]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000710/WC500023755.pdf.
4. European Medicines Agency. Committee for Human Medicinal Products (CHMP) Assessment report for Celvapan. EMEA/CHMP/629184/2009, [accessed 18.03.11]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000982/WC500022669.pdf.
5. European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. Revision 1.1 adopted by CHMP on 24 September 2009. EMEA/359381/2009, [accessed 18.03.11]. http://www.ema.europa.eu/pdfs/human/pandemicinfluenza/35938109en.pdf.
6. European Medicines Agency. Committee for Human Medicinal Products (CHMP) Guideline on the conduct of pharmacovigilance for vaccines for pre- and post-exposure prophylaxis against infectious diseases. EMEA/CHMP/PhVWP/503449/2007, [accessed 18.03.11]. http://www.ema.europa.eu/pdfs/human/phvwp/50344907en.pdf.
7. European Medicines Agency. EudraVigilance, [accessed 18.03.11]. http://eudravigilance.ema.europa.eu/human/index.asp.
8. European Medicines Agency. Twenty-second pandemic pharmacovigilance update. EMA/527985/2010, [accessed 18.03.11]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/08/WC500095870.pdf.
9. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302(7):750-757.
10. Bonanni P., Cohet C., Kjaer S.K., Latham N.B., Lambert P.H., Reisinger K., et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010, 28(30):4719-4730.
11. Canfell K. Monitoring HPV vaccination programmes. BMJ 2010, 340:c1666. 10.1136/bmj.c1666.
12. Black S., Eskola J., Siegriest C.A., Halsey N., MacDonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009, 374(9707):2115-2122. [Epub 2009 October 13].
13. McGrogan A., Madle G.C., Seaman H.E., deVries C. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009, 32:150-163.
14. Vellozzi C., Burwen D.R., Dobardzic A., Ball R., Walton K., Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009, 27(15):2114-2120.
15. Brighton Collaboration. Case definitions, [accessed 18.03.11]. https://brightoncollaboration.org/public/what-we-do/standards/case-definitions.html.
16. Eurosurveillance Editorial Team ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Eurosurveillance 2009, 14(39):1.
17. VAESCO. Pandemic Influenza Vaccination Safety Assessment Network Europe (PIV SANE). Background rates of specified events of interest. Preliminary version January 2010 [unpublished].
18. Breslow N.E., Day N.E. Statistical methods in cancer research. Volume II-The design and analysis of cohort studies 1987, IARC Sci. Publ. No. 82, Lyon, p. 91-106.
19. European Medicines Agency. Guideline on the use of statistical signal detection methods in the Eudravigilance data analysis system, [accessed 18.03.11]. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011437.pdf.
20. Alvarez Y., Hidalgo-Simon A., Maignen F., Slattery J. Validation of statistical signal detection procedures in EudraVigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf 2010, 33(6):475-487.
21. Stephenson W.P., Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007, 16(4):359-365.
22. Pariente A., Gregoire F., Fourrier-Reglat, Haramburu F., Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007, 30(10):891-898.
23. Hanquet G., Van Damme P., Brasseur D., De Cuyper X., Gregor S., Holmberg M., et al. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine 2011, 29(3):370-377.
24. Iskander J., Haber P., Herrera G. Monitoring vaccine safety during an influenza pandemic. Yale J Biol Med 2005, 78(5):261-271.
25. European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. Adopted by CHMP in November 2006, [accessed 18.03.11]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051739.pdf.
26. The European Medicines Agency (EMEA), the European Centre for Disease Prevention and Control (ECDC), the Heads of Medicines Agencies (HMA). European strategy for Influenza A/H1N1 vaccine benefit-risk monitoring, [accessed 18.03.11]. http://www.ema.europa.eu/pdfs/human/pandemicinfluenza/european_strategy.pdf.
27. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following Influenza A(H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28(45):7248-7255.
28. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of ASO3B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649. 10.1136/bmj.c2649.
29. van Puijenbroek E.P., Broos N., van Grootheest K. Monitoring adverse events of the vaccination campaign against Influenza A(H1N1) in the Netherlands. Drug Saf 2010, 33(12):1097-1108.
30. Carmena A., Omenaca F., Tejedor J.C., Merino J.M., Vaman T., Dieussaert I., et al. Immunogenicity and safety of ASO3-adjuvanted A H1N1 vaccine in children 6-35 months. Vaccine 2010, 28(36):5837-5844.
31. Clark T.W., Pareek M., Hoschler K., Dillon H., Nichoson K.G., Groth N., et al. Trial of 2009 Influenza A(H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
32. Grimaldi-Bensousa L., Rossignol M., Magy L., Cosson A., Abenhaim L. Risk of Guillain-Barré syndrome and vaccination against seasonal flu. Pharmacoepidemiol Drug Saf 2010, 19(S):S327.
33. Bardage C., Ohagen P., Olsson J., Persson I., Bergman U., Ortqvist A. Safety of pandemic flu vaccine in the population of Stockholm, Sweden: first, preliminary, data. Pharmacoepidemiol Drug Saf 2010, 19(S):S329.
34. Bone A., Guthmann J.P., Nicolau J., Lévy-Bruhl D. Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign. Vaccine 2010, 28(51):8157-8161.
35. Mereckiene J, on behalf of the VENICE Consortium. Overview of pandemic A(H1N1) 2009 influenza vaccination in Europe. Preliminary results of survey conducted by VENICE, 2010. ESCAIDE, Lisboa, Portugal, 13th November 2010, [accessed 18.03.11]. http://ecdc.europa.eu/en/ESCAIDE/ESCAIDE%2520Presentations%2520library/ESCAIDE2010_Late_Breakers_Mereckiene.pdf.
36. De Stefano F., Tokars J. H1N1 vaccine safety monitoring: beyond background rates. Lancet 2010, 375(9721):1146-1147.
37. Bryan P., Seabrooke S., Davies C. H1N1 vaccine safety: real-time surveillance in the UK. Lancet 2010, 376(9739):417-418.
38. Rüggeberg J.U., Gold M., Bayas J.M., Blum M.D., Bonhoffer J., Friedlander S., et al. Anaphylaxis: case definition and guideline for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5675-5684.
39. Safranek T.J., Lawrence D.N., Kurland L.T., Culver D.H., Wiederholt D.C., Hayner N.S., et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991, 133(9):940-951.
40. Haber P., DeStefano F., Angulo F.J., Iskander J., Shadomy S.V., Weintraub E., et al. Guillain-Barré syndrome following influenza vaccination. JAMA 2004, 292(20):2478-2481.
41. European Medicines Agency. Sixteenth pandemic pharmacovigilance update. EMA/255907/2010, [accessed 18.03.11]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/04/WC500089611.pdf.
42. Centers for Disease Control and Prevention (CDC) Preliminary results: surveillance for Guillain-Barré syndrome after receipt of Influenza A (H1N1) 2009 monovalent vaccine-United States, 2009-2010. MMWR Morb Mortal Wkly Rep 2010, 59(21):657-661.
43. Chen R.T., DeStefano F., Davis R.L., Jackson L.A., Thompson R.S., Mullooly J.P., et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000, 78(2):186-194.